Selected Announcements: Fuliwang's net profit in the first quarter is expected to increase by 183.84% to 254.81% year-on-year; Putailai plans to invest $297 million to build a Malaysia-based anode material production facility

People’s Financial News, March 11 — [Operational Data] Fulwin: Net profit attributable to parent in Q1 2026 is expected to increase by 183.84% to 254.81% year-on-year. Qide New Materials: Net profit for 2025 is expected to grow by 125.99% year-on-year, with a proposed dividend of 10 shares for every 1.2 yuan. Xiaoxiong Electric: Performance Express for 2025 reports net profit of 401 million yuan, up 39.17% year-on-year. Tanyou Food: Net profit for 2025 decreased by 8.79% year-on-year, with a proposed dividend of 0.55 yuan per share. Yiwe Communication: Performance Express for 2025 reports net profit of 75.144 million yuan, down 52.62% year-on-year. JAC Motors: February sales volume was 20,338 units, down 24.51% year-on-year. Xincheng Holdings: Contract sales amount in February decreased by 37.57% year-on-year. China MCC: New signed contract value from January to February was 132.44 billion yuan. Xintian Green Energy: Power generation in February was 1.3548 million MWh, a decrease of 4.65% year-on-year. [Refinancing] Wanwei High-tech: Plans to raise no more than 3 billion yuan from controlling shareholders via private placement for projects including polyvinyl alcohol resin. Yiyatong: Plans to issue non-public company bonds of no more than 3 billion yuan. Huafeng Technology: Application for stock issuance to specific targets approved and registered by China Securities Regulatory Commission. Starda Semiconductor: Application for issuance of convertible corporate bonds to specific targets approved and registered by China Securities Regulatory Commission. [Equity Changes] Jiuliang Shares: Huailong Investment plans to acquire 8.56% of the company’s shares. Tianfu Cultural Tourism: Controlling shareholder signed an agreement for free transfer of equity. [Increase/Decrease in Holdings, Buybacks] Shenghui Technology: Directors plan to reduce holdings by no more than 1.01%. Feirongda: Specific shareholders and directors plan to collectively reduce holdings by no more than 0.35%. [Bid Contracts] China Power Construction: The joint venture signed a highway design and construction general contracting contract worth approximately 5.636 billion yuan. Runjian Shares: Won an 840 million yuan bid for the Baoding Fuping Jinghui 500MW photovoltaic power project. Jinjiang Shipping: Subsidiary signed four container shipbuilding contracts totaling 820 million yuan. Shanxi Construction: Subsidiary awarded a 596 million yuan EPC project. China Tianying: Subsidiary jointly awarded the Yanliang District urban sanitation service project. [Major Investments] Putailai: Plans to invest $297 million to build a Malaysian anode material production base. Xinguodu: Plans to establish a holding subsidiary, JiSuan, to develop next-generation smart hardware. [Others] Dingxin Communications: The market access bans by State Grid and China Southern Power Grid have expired, but company-level and provincial-level bidding will gradually resume. Xinliang Dairy: Planning to issue H-shares and list on the Hong Kong Stock Exchange. Huicheng Environmental Protection: The 200,000-ton/year mixed waste plastic chemical recycling industrial pilot plant resumed production on March 9. Jinrui Mining: Fully owned subsidiary completed routine shutdown and maintenance and resumed production. Fangbang Shares: Subsidiary plans to acquire 1.07% of Zhongke Sihé for 20 million yuan. Zhenxin Technology: Shareholders sued the company, claiming the shareholders’ meeting resolution was invalid. Zhejiang Rontai: Plans to change external investment projects. Zunyoupin: Terminated the issuance of stocks to specific targets. Sanchuang Electronics: Elected Xiaowei as chairman. Xingqi Eye Medicine: First patient enrolled in Phase I clinical trial of SQ-24071 eye drops. Hengrui Medicine: SHR-2524 injection drug clinical trial approved. Hengrui Medicine: Injection SHR-9803 drug clinical trial approved. Wusheng Biological: Application for clinical trial of human umbilical cord mesenchymal stem cell type II injection approved. East China Medicine: Subsidiary’s injection HDM2024 approved for clinical trial in the United States.